Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)...Ho Ho Ho off I go, good to see all my old friends again, even the ones that have been burned in the past apparently.
Here comes the shorts...What a song, anybody ever wonder why a moderator is a decelerator ???
I love it, all of our good old friends are back...tic toc tic toc Value will ...FDA & away...
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)
So as I’ve posted long before, the advanced Algorithms (ANN) will prove pivotal in this study end results, will the FDA sneeze at this disruptive technology, some day the dice will stop rolling...
From my previous PPS post:
5/13/2020:
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)
It’s been a long long road to follow, with many curves, but the story line builds to a much needed product that works, where others don’t. Unfortunately most investors want to know the story, but only have the patience (or laziness to do no research) to wait for a fast food burger/fries with a Diet Coke (I like rum & cokes :)... !!! 13
Interesting nurse Barb & Cyrcadia LLBO Board member( Shyamali Mallick Singhal, Medical Director El Camino Cancer Center-MD, PhD, FACS ) work at El Camino where the CMD formally iT Bra pilot study (reconfirming ANN -AI artificial intelligence modified algorithm) can improve end specificity results ...((“Further refinement of the neural net algorithm”(ANN- foundation of artificial intelligence (AI) and solves problems that would prove impossible or difficult by human or statistical standards. ANNs have self-learning capabilities that enable them to produce better results as “more data becomes available”. (This is why Cyrcadia is building the largest breast data -data base, as they have previously mentioned- “transferred to a global cancer library where advanced analytical analysis occurs” ) is required in order to shorten the period of data recording and improve “specificity.”
)Principal Investigator
Shiva Singhal, MD
Sponsor
Cyrcadia, Inc.) recognize the name !
Certainly sounds like as previously quoted by past researchers as Disruptive Technology...tic toc
Abstracts tying into each other, the noose tightens, the dice roll Sep, 2020
2020 Sep
Abstract:
“An introduction to the Cyrcadia Breast Monitor: A wearable breast health monitoring device”
Vinitha Sree S et al. Comput Methods Programs Biomed. 2020 Dec.
excerpt: A pilot study of 173 female study subjects is underway, in order to validate this predictive model in an independent test population.
((On Cyrcadia board: Shyamali Mallick Singhal, Medical Director El Camino Cancer Center-MD, PhD, FACS ))
2009
Abstract: “Comparative study on the use of analytical software to identify the different stages of breast cancer using discrete temperature data”
excerpt: “Based on these evaluations, this current effort shows the feasibility of applying analytical software techniques together with the real-time functional thermal analysis to develop a potential tool for the detection and classification of breast cancer 2009”
Joanna M Y Tan et al. J Med Syst. 2009 Apr. Authors
Joanna M Y Tan 1 , E Y K Ng, Rajendra U Acharya, Louis G Keith, Jim Holmes
2006
Abstract: “The potential role of dynamic thermal analysis in breast cancer detection”
M Salhab et al. Int Semin Surg Oncol. 2006.
14: Salhab M, Al Sarakbi W, Mokbel K. The evolving role of the dynamic thermal analysis in the early detection of breast cancer. Int Semin Surg Oncol. 2005;2:8. doi: 10.1186/1477-7800-2-8. - DOI - PMC - PubMed
excerpt-
“The Future:
Dynamic thermal analysis of the breast is a safe, non invasive approach that seems to be sensitive for the early detection of breast cancer especially in young women where the conventional mammography is of limited value. Such a technology could become the initial breast screening test in pre-menopausal women and those who are classified as positive can then be selected for anatomical imaging with mammography, MRI and/or ultrasonography. “Further refinement of the neural net algorithm”(ANN- foundation of artificial intelligence (AI) and solves problems that would prove impossible or difficult by human or statistical standards. ANNs have self-learning capabilities that enable them to produce better results as “more data becomes available”. (This is why Cyrcadia is build the largest breast data data base, as they have previously mentioned- “transferred to a global cancer library where advanced analytical analysis occurs” ) is required in order to shorten the period of data recording and improve specificity. Prospective multi-centre trials are then required to validate these promising observations.”
The Clinical Trial Gov site:
To determine the accuracy of this device, it will be tested on a group of women who have been scheduled for a breast biopsy due to a suspicious imaging test.
Principal Investigator
Shiva Singhal, MD medical Director El Camino Hospital
Sponsor
Cyrcadia, Inc.
NCT Number
NCT02511301
Contact
Kara Turner, Clinical Research Coordinator
Taft Center for Clinical Research
650-962-4562
Kara_Turner@elcaminohealth.org
For more information about this clinical trial, including trial status, eligibility and full trial listing, visit www.clinicaltrials.gov.
((Other endpoints of the study are:
* to determine the accuracy of Cyrcadia CBR™, including the positive predictive value, negative predictive value, false negative rate and false positive rate.
* to determine the optimal wear time for the Cyrcadia CBR™.
* to demonstrate “”substantial equivalent or improved results”” when applied to Cyrcadia original patient case study with identical ANN-advanced neural network analysis computational results.
Study subjects will be followed at 6, 12, 18, and 24 months to update their clinical status.
Study Design
(Clinical Trial)
Estimated Enrollment :
173 participants
Primary Purpose:
Screening
Official Title:
Circadian Thermal Sensing for the Detection of Breast Disease as a Supplemental Cancer Screening System
Study Start Date :
June 2015
Estimated Primary Completion Date :
February 2020
Estimated Study Completion Date :
February 2020))
So as I’ve posted long before, the advanced Algorithms (ANN) will prove pivotal in this study end results, will the FDA sneeze at this disruptive technology, some day the dice will stop rolling...
From my previous PPS post:
5/13/2020:
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)
It’s been a long long road to follow, with many curves, but the story line builds to a much needed product that works, where others don’t. Unfortunately most investors want to know the story, but only have the patience (or laziness to do no research) to wait for a fast food burger/fries with a Diet Coke (I like rum & cokes :)... !!! 13
Who knows, maybe the next GameStop, but given values today probably not, OH I meant human life not monetary greed...
Before April 2006:
173 women undergoing mammography as part of clinical assessment of their breast symptoms were recruited prior to having a biopsy. Thermal data from the breast surface were collected every five minutes for a period of 48 hours using eight thermal sensors placed on each breast surface [First Warning System (FWS), Lifeline Biotechnologies, Florida, USA]. Thermal data were recorded by microprocessors during the test period and analysed using specially developed statistical software. Temperature points from each contra-lateral sensor are plotted against each other to form a thermal motion picture of a lesion's physiological activity. DTA interpretations [positive (abnormal thermal signature) and negative (normal thermal signature)] were compared with mammography and final histology findings.
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/
“The potential role of dynamic thermal analysis in breast cancer detection”
173 is also current trial target : as previously posted
Study Design
(Clinical Trial)
Estimated Enrollment :
173 participants
Primary Purpose:
Screening
Official Title:
Circadian Thermal Sensing for the Detection of Breast Disease as a Supplemental Cancer Screening System
Study Start Date :
June 2015
Estimated Primary Completion Date :
February 2020
Estimated Study Completion Date :
February 2020))
Interesting nurse Barb & Cyrcadia LLBO Board member( Shyamali Mallick Singhal, Medical Director El Camino Cancer Center-MD, PhD, FACS ) work at El Camino where the CMD formally iT Bra pilot study (reconfirming ANN -AI artificial intelligence modified algorithm) can improve end specificity results ...((“Further refinement of the neural net algorithm”(ANN- foundation of artificial intelligence (AI) and solves problems that would prove impossible or difficult by human or statistical standards. ANNs have self-learning capabilities that enable them to produce better results as “more data becomes available”. (This is why Cyrcadia is building the largest breast data -data base, as they have previously mentioned- “transferred to a global cancer library where advanced analytical analysis occurs” ) is required in order to shorten the period of data recording and improve “specificity.”
)Principal Investigator
Shiva Singhal, MD
Sponsor
Cyrcadia, Inc.) recognize the name !
Certainly sounds like as previously quoted by past researchers as Disruptive Technology...tic toc
Abstracts tying into each other, the noose tightens, the dice roll Sep, 2020
2020 Sep
Abstract:
“An introduction to the Cyrcadia Breast Monitor: A wearable breast health monitoring device”
Vinitha Sree S et al. Comput Methods Programs Biomed. 2020 Dec.
excerpt: A pilot study of 173 female study subjects is underway, in order to validate this predictive model in an independent test population.
((On Cyrcadia board: Shyamali Mallick Singhal, Medical Director El Camino Cancer Center-MD, PhD, FACS ))
2009
Abstract: “Comparative study on the use of analytical software to identify the different stages of breast cancer using discrete temperature data”
excerpt: “Based on these evaluations, this current effort shows the feasibility of applying analytical software techniques together with the real-time functional thermal analysis to develop a potential tool for the detection and classification of breast cancer 2009”
Joanna M Y Tan et al. J Med Syst. 2009 Apr. Authors
Joanna M Y Tan 1 , E Y K Ng, Rajendra U Acharya, Louis G Keith, Jim Holmes
2006
Abstract: “The potential role of dynamic thermal analysis in breast cancer detection”
M Salhab et al. Int Semin Surg Oncol. 2006.
14: Salhab M, Al Sarakbi W, Mokbel K. The evolving role of the dynamic thermal analysis in the early detection of breast cancer. Int Semin Surg Oncol. 2005;2:8. doi: 10.1186/1477-7800-2-8. - DOI - PMC - PubMed
excerpt-
“The Future:
Dynamic thermal analysis of the breast is a safe, non invasive approach that seems to be sensitive for the early detection of breast cancer especially in young women where the conventional mammography is of limited value. Such a technology could become the initial breast screening test in pre-menopausal women and those who are classified as positive can then be selected for anatomical imaging with mammography, MRI and/or ultrasonography. “Further refinement of the neural net algorithm”(ANN- foundation of artificial intelligence (AI) and solves problems that would prove impossible or difficult by human or statistical standards. ANNs have self-learning capabilities that enable them to produce better results as “more data becomes available”. (This is why Cyrcadia is build the largest breast data data base, as they have previously mentioned- “transferred to a global cancer library where advanced analytical analysis occurs” ) is required in order to shorten the period of data recording and improve specificity. Prospective multi-centre trials are then required to validate these promising observations.”
The Clinical Trial Gov site:
To determine the accuracy of this device, it will be tested on a group of women who have been scheduled for a breast biopsy due to a suspicious imaging test.
Principal Investigator
Shiva Singhal, MD medical Director El Camino Hospital
Sponsor
Cyrcadia, Inc.
NCT Number
NCT02511301
Contact
Kara Turner, Clinical Research Coordinator
Taft Center for Clinical Research
650-962-4562
Kara_Turner@elcaminohealth.org
For more information about this clinical trial, including trial status, eligibility and full trial listing, visit www.clinicaltrials.gov.
((Other endpoints of the study are:
* to determine the accuracy of Cyrcadia CBR™, including the positive predictive value, negative predictive value, false negative rate and false positive rate.
* to determine the optimal wear time for the Cyrcadia CBR™.
* to demonstrate “”substantial equivalent or improved results”” when applied to Cyrcadia original patient case study with identical ANN-advanced neural network analysis computational results.
Study subjects will be followed at 6, 12, 18, and 24 months to update their clinical status.
Study Design
(Clinical Trial)
Estimated Enrollment :
173 participants
Primary Purpose:
Screening
Official Title:
Circadian Thermal Sensing for the Detection of Breast Disease as a Supplemental Cancer Screening System
Study Start Date :
June 2015
Estimated Primary Completion Date :
February 2020
Estimated Study Completion Date :
February 2020))
So as I’ve posted long before, the advanced Algorithms (ANN) will prove pivotal in this study end results, will the FDA sneeze at this disruptive technology, some day the dice will stop rolling...
From my previous PPS post:
5/13/2020:
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)
It’s been a long long road to follow, with many curves, but the story line builds to a much needed product that works, where others don’t. Unfortunately most investors want to know the story, but only have the patience (or laziness to do no research) to wait for a fast food burger/fries with a Diet Coke (I like rum & cokes :)... !!! 13
It’s the investment that’s relevant...smart people do not make dumb investments generally speaking.
It’s a real Co. with a real product that’s needed, no doubt about that. So the craps dice roll on...at some point they’ll stop!
Old news, but I Love reading it iFlytec is NO schmuck Co. (Not is Dr. Tao)
HONG KONG, July 16, 2018 /PRNewswire/ -- iFlytek, the largest publicly-listed AI technology company in the Asia-Pacific region has further advanced its healthcare initiative by leading the Pre-A round investment into Cyrcadia Asia, a company developing a smart wearable bra insert that provides accurate early breast cancer detection.
While iFlytek is already a recognised a leader in speech technologies, it has made recent advances in AI applications for healthcare. In November 2017, the company grabbed attention when its "Xiaoyi" AI-powered robot successfully aced the national medical exam, the qualifying test for doctors in China, with 456 points, 96 points above the pass mark. iFlytek Health has now deployed its AI capability in over 50 hospitals in its native Anhui Province, China, to provide support to general practitioners in diagnosis and treatment, and in interpreting medical images including breast imaging. iFlytek Health, its healthcare division established in 2016, is headed by CEO Dr Tao Xiaodong, a veteran technologist of Philips and GE Healthcare who brings a wealth of expertise in medical imaging and computer-aided diagnostics. Dr Tao also joins the board of Cyrcadia Asia.
Cyrcadia closes its Pre-A round with a total raise of US$3.8 million. Following iFlytek's lead in the round were a number of other Asian investment funds and private investors. The Pre-A funding enables Cyrcadia to complete product development and launch into Hong Kong and other Asian markets in late 2018. Cyrcadia's device is a revolutionary sensor patch worn under a women's bra which, with two hours of monthly wear, allows women to monitor their breast health from an app on their mobile phone. The technology uses cloud-based AI to monitor for circadian metabolic changes that are proven to correlate to the onset of cancer. The technology has particular advantages in Asia, where screening participation is low, cancer incidence rates are increasing, and where the majority of the female population have dense breast tissue, for which traditional imaging technologies are less accurate.
Cyrcadia's launch in Asia makes use of over 10 years of research, extensive trials in the US and an existing US FDA 510k clearance. The product development has been backed by Nypro, the specialist medical device division of global manufacturing services company Jabil (NYSE: JBL) and production is scheduled to start at Nypro's Shanghai facility in summer of 2018.
Commenting on the deal, Tao Xiaodong said: "We are excited to play a leading role in the development and launch of Cyrcadia's technology. iFlytek is already harnessing the power of AI in healthcare, but Cyrcadia's technology, by using metabolic change to detect disease, can leapfrog many of the current drawbacks of imaging and human interpretation. We are also excited by the promise of Cyrcadia's technology as a consumer wearable device, providing real-time monitoring for women at their own convenience. As Cyrcadia's user base grows, it has the potential to be the world's largest data base of breast health and breast cancer incidence, and we hope in the near future we can make a major contribution to research, prevention and treatment of the disease."
People relax, I just talk to Joe Biden, and he says he will have Jim return our emails in a more timely manner, or he will have him censored...
Friday, 05/22/20 09:01:38 AM
Re: yaro1 post# 30471 0
Post # of 30885
Not necessarily, we already have FDA class ll approval, but changes to the product as I mentioned a few post back require recertification—“substantially equivalent” SE to be marketed, Quote, ”Until the submitter receives an order declaring a device SE, the submitter may not proceed to market the device. Once the device is determined to be SE, it can then be marketed in the U.S. The SE determination is usually made within “90 days” and is made based on the information submitted by the submitter.”
—Article: “We're going to see a lot more consumer tech devices get the FDA's blessing. Here's what you need to know. June 13, 2019 5:00 a.m. PT”
So we do know for fact: Ongoing El Camino trial means CBM is being “funded & tested”...! (My Investment experience means those words are “code” for 1), El Camino sees “”merit/potential efficacy in the CBM””
or it simply would not be allowed anywhere near their facilities ((Actually their very words when Trials started NOT Cyrcadia’s)) & 2)LLBO outstanding O/S has not been further diluted, due to the Cyrcadia restructuring several years ago ((and private funding I posted recently, JH)) with Cyrcadia incurring the additional funding for the on going trials...without having to issue any more LLBO shares @ sub penny valuation.
“Elementary, my dear Watson”
You know this stock is like a big big big Craps table, you buy the dice (bet on a number) & roll them, but they just keep rolling in perpetual motion, someday the dice will stop rolling & land on a number...? Every day the dice are slowing down...!!!
There’s no thought needed in an eventual buyout occurring whenever the CBM Cyrcadia Breast Monitor
has full approval & distribution is to begin.
One of their early venture investors required it as a requirement to capital funding. I’d posted this several years ago. Now it’s part of my long repost, I occasionally bring back to the top.
(& no I’m not searching for it, it’s in prior post find it)
Trial:
The https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2018-02060&r=1
Trial Objectives and Outline
The Cyrcadia CBR™ (Circadian Biometric Recorder) includes wearable biometric patches and a
detachable data recording device. The CBR™ records chronobiologic data while the patient is
totally ambulatory and going about her normal daily routine. Following removal of the
detachable data recording device from the wearable biometric patches, the data is transferred
to a computer for analysis. The Cyrcadia CBR™ will be placed on the patient for the duration
of 2 to 24 hours. There is no restriction of daily activity. The study subject is requested
to sponge bathe rather than shower while wearing the device, keeping the device dry during
the testing procedure. After this period, the CBR™ will be removed and the data will be
transferred to a computer for analysis.
The primary endpoint of this 173 patient study is to determine the accuracy of Cyrcadia CBR™
as a supplemental screening device to mammography and ultrasound in predicting a diagnosis of
breast cancer. Specific emphasis will be on the utilization of the CBR as a secondary
screening device to reduce the number of biopsies currently performed on non-cancerous
tissue. A secondary emphasis will be on the CBR to act as an improved screening solution over
mammography specifically in those patients with dense breast parenchymal tissue.
Other endpoints of the study are:
- to determine the accuracy of Cyrcadia CBR™, including the positive predictive value,
negative predictive value, false negative rate and false positive rate.
- to determine the optimal wear time for the Cyrcadia CBR™.
- to demonstrate substantial equivalent or improved results when applied to Cyrcadia
original patient case study with identical advanced neural network analysis
computational results.
Study subjects will be followed at 6, 12, 18, and 24 months to update their clinical status.
Interesting, Covid was starting to grip China during this CNBC Cyrcadia Asia interview...
https://www.cnbc.com/video/2019/11/08/the-new-technologies-transforming-CNBC’s Chery Kang sits down with Serena Shao, Head of Healthcare Research, China Credit Suisse and Rob Royea CEO & Co-Founder Cyrcadia Asia.
FRI, NOV 8 201911:58 AM EST
Happyyy New Year to all...tic toc...
“We have had a great deal of interest in this technology that may change the need for a breast biopsy,” said Dr. Shyamali Singhal, founder of the El Camino Hospital Cancer Center. “The trial at El Camino Hospital opened with strong interest from the patient population and the early results are indeed promising. We look forward to further involvement with the Cyrcadia study here at El Camino Hospital.”
Hah ha hahhh ha ha, buy all u can folks. 13
Hah ha hahhh ha ha, buy all u can folks. 13
No equity financing (no stock dilution), but trials supported by private debt financing (good sign, because the owners “stock holders”, especially those that know far more than us reap more profits).
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)
Fortune Business Insights:
Global | Published Date: Jul, 2019 | Report ID: FBI101065-
“The global telehealth market size valued at USD 49.8 Billion in 2018 and is projected to reach USD 266.8 Billion by 2026, exhibiting a CAGR of 23.4% between 2018 and 2026”
EBITDA valuation: for co’s up to $100Mil.Rev., is normally 5-7x EBITDA(Earnings before interest taxes depreciation and amortization)
40,000,000Mil mammograms yr USA, not including the rest of the world ( or the high dense breast incidents in Asia ), LLBO gets 10% = 4,000,000mil x *$150ea=Revenue of 600,000Mil & avg gross EBITDA profit of 45% =
about $270,000,000 Million,
Value Cyrcadia Health at 5X that profit =(270mil x 5= $1.5 Billion), So
LLBO PPS fair value (LLBO owns 30% of Cyrcadia or $450 Million) so 3.1bill OS share ($.145 PPS)
Now obviously something as big as breast cancer and the need for alternative solutions share price could fluctuate to higher levels on speculation ???
*($150-estimated annual iTBra fee per Cyrcadia)
iTBra FDA Class ll:
FDA class II Substantially changed devices will need to be reviewed before marketing clearance will be issued by the fda...
(simply put can’t market the device due to device applied application time/ AI software changes are re approved )
Your Probably aware the iT Bra went through technology upgrades, these changes substantially changed the
efficacy for the better, but still need FDA review.
This is why their website states-“The product is not currently available for sale in the United States.“
& Cyrcadia Asia states ”FDA Class II clearance issued with further clearances in process.”
Will Covid-19 hasten or impede the FDA & US continued trial...will see ! iFlytec(Keda Xunfei) & Cyrcadia Health
post# 27374
Re-Post: New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the iTBra tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some iTBras...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
#27171 PHd cancer researcher perspective Hint: U may be induced to buy more shares!
27131 PPS it’s long,but conclusion: pps.22 or more
27094 Co marketing intent: the short “it’s happening”!
27061 Market size & Need: Summary-It’s Huge & Needed
26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$
27037 Number of breast cancer cases & importance of earl detection: Your life may depend on it
26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Bloomberg Nov, 2017 iFlytec video (6 months After Cyrcadia Asia iT Bra investment)
“China’s iFlytec focuses on smart healthcare” quoted...
—“Smart Healthcare growth (acquisition) is the primary Company smart tech strategic focus”
—Assisted diognostic system accuracy for improved cancer diognosis through AI imaging”
—“Out International strategy of investing in USA Co’s WILL assist this goal”
—Activities are being conducted at our new Silicon Valley...
Read between the lines, LLBO S/B trading above .05 cents per share.
Jim Holmes, Lifeline’sCyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually”. (PPS anybody’s guess ?)
Thought about Spam for Thanksgiving, but instead I bought some more LLBO shares...
“In future, artificial intelligence will help to diagnose patients and develop the medicine required at "very low costs," says venture capitalist Tim Draper.“
Maybe she will leave a dime under my pillow. 13...
https://www.msn.com/en-us/money/other/health-care-is-going-digital-and-that-could-make-it-almost-free-says-tech-investor-tim-draper/ar-BB1bkMRa?li=BBnb7Kz
(I have a great product idea we will develop a product that allows a women to examine her breast in the comfort of her home, Which will eliminate the expense of traveling to the doctors office, Expensive medical exams and simply the price of privacy ! We will call this product the Smart Bra or Breast Monitor, well why not just call it
Cyrcadia Breast Monitor CBM...What a great idea...!)
Exact Science is on a buying frenzy...maybe we’re next. You never really know ?
Just positioned GTC orders on 3 million shares LLBO
(Interesting they notice us !)
Goodwill, story line, needed technology, etc all the above. 13...
PPS LLBO (Thnx for update E-7-2)
Cyrcadia Breast Monitor System-
CBM
PPS Target—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)
Fortune Business Insights:
Global | Published Date: Jul, 2019 | Report ID: FBI101065-
“The global telehealth market size valued at USD 49.8 Billion in 2018 and is projected to reach USD 266.8 Billion by 2026, exhibiting a CAGR of 23.4% between 2018 and 2026”
********************************************************
PubMed.gov
An introduction to the Cyrcadia Breast Monitor: A wearable breast health monitoring device.
S VS, et al. Comput Methods Programs Biomed. 2020. PMID: 33007593
CONCLUSIONS: The results from the initial studies indicate that the CBM may be valuable for breast health monitoring un …Below,
An introduction to the Cyrcadia Breast Monitor: A wearable breast health monitoring device
Vinitha Sree S et al. Comput Methods Programs Biomed. 2020.
Show details
Cite
Abstract:
Background: The most common breast cancer detection modalities are generally limited by radiation exposure, discomfort, high costs, inter-observer variabilities in image interpretation, and low sensitivity in detecting cancer in dense breast tissue. Therefore, there is a clear need for an affordable and effective adjunct modality that can address these limitations. The Cyrcadia Breast Monitor (CBM) is a non-invasive, non-compressive, and non-radiogenic wearable device developed as an adjunct to current modalities to assist in the detection of breast tissue abnormalities in any type of breast tissue.
Methods: The CBM records thermodynamic metabolic data from the breast skin surface over a period of time using two wearable biometric patches consisting of eight sensors each and a data recording device. The acquired multi-dimensional temperature time series data are analyzed to determine the presence of breast tissue abnormalities. The objective of this paper is to present the scientific background of CBM and also to describe the history around the design and development of the technology.
Results: The results of using the CBM device in the initial clinical studies are also presented. Twenty four-hour long breast skin temperature circadian rhythm data was collected from 93 benign and 108 malignant female study subjects in the initial clinical studies. The predictive model developed using these datasets could differentiate benign and malignant lesions with 78% accuracy, 83.6% sensitivity and 71.5% specificity. A pilot study of 173 female study subjects is underway, in order to validate this predictive model in an independent test population.
Conclusions: The results from the initial studies indicate that the CBM may be valuable for breast health monitoring under physician supervision for confirmation of any abnormal changes, potentially prior to other methods, such as, biopsies. Studies are being conducted and planned to validate the technology and also to evaluate its ability as an adjunct breast health monitoring device for identifying abnormalities in difficult-to-diagnose dense breast tissue.
Keywords: Breast cancer; Circadian rhythm; Data mining; Machine learning; Predictive analytics; Thermal metabolomics; Wearable device.
Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest The authors of this work declare that they have no conflicts of interest.
***********************************************************
post# 27374
Re-Post: New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the Cyrcadia Breast Monitor -tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some Cyrcadia Breast Monitors...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
Post# 27171
PHd cancer researcher perspective Hint: U may be induced to buy more shares!
Post# 27131 PPS it’s long,but conclusion: pps.22 or more (updated per above $.14 PPS)
Post#27094 Co marketing intent: the short “it’s happening”!
Post# 27061 Market size & Need: Summary-It’s Huge & Needed
Post# 26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$ (Insurance CO’s want this money saving technology)
Post #27037 Number of breast cancer cases & importance of early detection: “Your life may depend on it”.
Post#26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
Post#25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Jim Holmes, Lifeline’sCyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually. (PPS anybody’s guess ?)
iFlytec(Keda Xunfei) & Cyrcadia Health
Bloomberg Nov, 2017 iFlytec video (6 months after iT Bra investment)
“China’s iFlytec focuses on smart healthcare” quoted saying...
—“Smart Healthcare growth (acquisition) is the primary Company smart tech strategic focus”
—Assisted diognostic system accuracy for improved cancer diognosis through AI imaging”
—“Out International strategy of investing in USA Co’s WILL assist this goal”
—Activities are being conducted at our new Silicon Valley office”
Read between the lines, LLBO S/B trading above .05 cents per share.
Post#3095...pps
https://electronichealthreporter.com/tag/itbra/
Still talkin about us...
FDA 3/27/19 —
FDA Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D. “Given that more than half of women over the age of 40 in the U.S. have dense breasts, helping to ensure patient access to information about the impact that breast density and other factors can have on the risk for developing breast cancer is an important part of a comprehensive breast health strategy. Today’s proposed amendments are part of the agency’s broader commitment to supporting “”new innovations”” and methods to prevent, detect and treat cancer. We are dedicated to working across the agency and with stakeholders to provide patients with tools and information to fight breast cancer effectively.”
Come on man...we have the machine gun, put the swords away!!!
Good PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)
Fortune Business Insights:
Global | Published Date: Jul, 2019 | Report ID: FBI101065-
“The global telehealth market size valued at USD 49.8 Billion in 2018 and is projected to reach USD 266.8 Billion by 2026, exhibiting a CAGR of 23.4% between 2018 and 2026”
EBITDA valuation: for co’s up to $100Mil.Rev., is normally 5-7x EBITDA(Earnings before interest taxes depreciation and amortization)
40,000,000Mil mammograms yr USA, not including the rest of the world ( or the high dense breast incidents in Asia ), LLBO gets 10% = 4,000,000mil x *$150ea=Revenue of 600,000Mil & avg gross EBITDA profit of 45% =
about $270,000,000 Million,
Value Cyrcadia Health at 5X that profit =(270mil x 5= $1.5 Billion), So
LLBO PPS fair value (LLBO owns 30% of Cyrcadia or $450 Million) so 3.1bill OS share ($.145 PPS)
Now obviously something as big as breast cancer and the need for alternative solutions share price could fluctuate to higher levels on speculation ???
*($150-estimated annual iTBra fee per Cyrcadia)
iTBra FDA Class ll:
FDA class II Substantially changed devices will need to be reviewed before marketing clearance will be issued by the fda...
(simply put can’t market the device due to device applied application time/ AI software changes are re approved )
Your Probably aware the iT Bra went through technology upgrades, these changes substantially changed the
efficacy for the better, but still need FDA review.
This is why their website states-“The product is not currently available for sale in the United States.“
& Cyrcadia Asia states ”FDA Class II clearance issued with further clearances in process.”
Will Covid-19 hasten or impede the FDA & US continued trial...will see ! iFlytec(Keda Xunfei) & Cyrcadia Health
post# 27374
Re-Post: New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the iTBra tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some iTBras...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
#27171 PHd cancer researcher perspective Hint: U may be induced to buy more shares!
27131 PPS it’s long,but conclusion: pps.22 or more
27094 Co marketing intent: the short “it’s happening”!
27061 Market size & Need: Summary-It’s Huge & Needed
26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$
27037 Number of breast cancer cases & importance of earl detection: Your life may depend on it
26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Bloomberg Nov, 2017 iFlytec video (6 months After Cyrcadia Asia iT Bra investment)
“China’s iFlytec focuses on smart healthcare” quoted...
—“Smart Healthcare growth (acquisition) is the primary Company smart tech strategic focus”
—Assisted diognostic system accuracy for improved cancer diognosis through AI imaging”
—“Out International strategy of investing in USA Co’s WILL assist this goal”
—Activities are being conducted at our new Silicon Valley...
Read between the lines, LLBO S/B trading above .05 cents per share.
Jim Holmes, Lifeline’sCyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually”. (PPS anybody’s guess ?)
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)
Fortune Business Insights:
Global | Published Date: Jul, 2019 | Report ID: FBI101065-
“The global telehealth market size valued at USD 49.8 Billion in 2018 and is projected to reach USD 266.8 Billion by 2026, exhibiting a CAGR of 23.4% between 2018 and 2026”
EBITDA valuation: for co’s up to $100Mil.Rev., is normally 5-7x EBITDA(Earnings before interest taxes depreciation and amortization)
40,000,000Mil mammograms yr USA, not including the rest of the world ( or the high dense breast incidents in Asia ), LLBO gets 10% = 4,000,000mil x *$150ea=Revenue of 600,000Mil & avg gross EBITDA profit of 45% =
about $270,000,000 Million,
Value Cyrcadia Health at 5X that profit =(270mil x 5= $1.5 Billion), So
LLBO PPS fair value (LLBO owns 30% of Cyrcadia or $450 Million) so 3.1bill OS share ($.145 PPS)
Now obviously something as big as breast cancer and the need for alternative solutions share price could fluctuate to higher levels on speculation ???
*($150-estimated annual iTBra fee per Cyrcadia)
iTBra FDA Class ll:
FDA class II Substantially changed devices will need to be reviewed before marketing clearance will be issued by the fda...
(simply put can’t market the device due to device applied application time/ AI software changes are re approved )
Your Probably aware the iT Bra went through technology upgrades, these changes substantially changed the
efficacy for the better, but still need FDA review.
This is why their website states-“The product is not currently available for sale in the United States.“
& Cyrcadia Asia states ”FDA Class II clearance issued with further clearances in process.”
Will Covid-19 hasten or impede the FDA & US continued trial...will see ! iFlytec(Keda Xunfei) & Cyrcadia Health
post# 27374
Re-Post: New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the iTBra tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some iTBras...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
#27171 PHd cancer researcher perspective Hint: U may be induced to buy more shares!
27131 PPS it’s long,but conclusion: pps.22 or more
27094 Co marketing intent: the short “it’s happening”!
27061 Market size & Need: Summary-It’s Huge & Needed
26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$
27037 Number of breast cancer cases & importance of earl detection: Your life may depend on it
26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Bloomberg Nov, 2017 iFlytec video (6 months After Cyrcadia Asia iT Bra investment)
“China’s iFlytec focuses on smart healthcare” quoted...
—“Smart Healthcare growth (acquisition) is the primary Company smart tech strategic focus”
—Assisted diognostic system accuracy for improved cancer diognosis through AI imaging”
—“Out International strategy of investing in USA Co’s WILL assist this goal”
—Activities are being conducted at our new Silicon Valley...
Read between the lines, LLBO S/B trading above .05 cents per share.
Jim Holmes, Lifeline’sCyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually”. (PPS anybody’s guess ?)
Ho Ho Ho happy 4th to the board scammers & bulls...13
Your welcome...did it twice, 1st post didn’t take WELL I guess it did!!!
Article AARP June 2020
The future of healthcare is here—“ The pandemic has turned telehealth from a maybe, one day to right here, right now‘“
“As recently as last year, only 8% of Americans had ever used telemedicine. That has changed overnight, with some practitioners reporting that up to 95% of patients visits are now “virtual”, and with insurance companies and health providers advertising their telemedicine offerings” “AI artificial intelligence increasingly used more ”etc etc tic toc ...
(FDA getting more heat to speed up AI artificial intelligence devices...Like the iTBra? !!!)13
Article: June 2020 AARP—The future of healthcare is here
“The pandemic has turned telehealth from a ‘maybe, one day’, to a ‘right here, right now’
“As recently as last year, only 8% of Americans had ever use telemedicine. That has changed overnight, with some practitioners reporting that up to 95% of patient visits are now “virtual”, and with insurance companies and health providers advertising their telemedicine offerings”, “AI artificial intelligence playing increasingly big role”
(Seems to me that was posted several years ago in my new investor information Post)!!! Tic toc...
FDA will be feeling the heat to move on the iTBra
I’m really surprised at some of the scum bags that are on this site...must be left wing racist liberals...
Who knows maybe the FDA is getting pressure to approve market clearance for this proven Class11 device, & someone is letting the beans spill ???
But, if that were the case the volume would be explosively higher & percentage gain most likely in the quad digit
range sending the stock on its way North...!
Wearable Healthcare/Medical Devices Market To Reach USD 32.57 Billion By 2027 | Top Players | Fitbit, Philips, Garmin, Lifewatch, Medtronic, NeuroMetrix
Reports And Data
March 4th, 2020 Releases
“The Global Wearable Healthcare/Medical Devices Market is expected to reach USD 32.57 billion by 2027, according to a new report released by Reports and Data. Increasing adoption of smartphone-based applications for healthcare monitoring by individuals as well as healthcare providers is a major cause for a rise in their demand.”
Cyrcadia Further key findings from the report suggest—
“Diagnostic and Monitoring Devices are expected to control a significant share of the overall market. Adoption of these devices can aid in the faster diagnosis of diseases like diabetes, hypertension, and cancer. The iTBra, developed by Cyrcadia Health (LLBO Lifeline Biotechnologies) can help detect breast cancer. According to the World Cancer Research Fund, more than 2 million new cases of breast cancer were registered in the year 2018. Belgium recorded the highest number of cases of breast cancer in women, followed by Luxembourg and the Netherlands. Adoption of these breast patches could help detect cancer even in dense breast tissue. Dense breast tissues are four to six times more likely to develop tumors. Breast patches will most likely decrease the number of breast biopsies significantly during the forecast years.”
Tic toc...13
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)
Fortune Business Insights:
Global | Published Date: Jul, 2019 | Report ID: FBI101065-
“The global telehealth market size valued at USD 49.8 Billion in 2018 and is projected to reach USD 266.8 Billion by 2026, exhibiting a CAGR of 23.4% between 2018 and 2026”
EBITDA valuation: for co’s up to $100Mil.Rev., is normally 5-7x EBITDA(Earnings before interest taxes depreciation and amortization)
40,000,000Mil mammograms yr USA, not including the rest of the world ( or the high dense breast incidents in Asia ), LLBO gets 10% = 4,000,000mil x *$150ea=Revenue of 600,000Mil & avg gross EBITDA profit of 45% =
about $270,000,000 Million,
Value Cyrcadia Health at 5X that profit =(270mil x 5= $1.5 Billion), So
LLBO PPS fair value (LLBO owns 30% of Cyrcadia or $450 Million) so 3.1bill OS share ($.145 PPS)
Now obviously something as big as breast cancer and the need for alternative solutions share price could fluctuate to higher levels on speculation ???
*($150-estimated annual iTBra fee per Cyrcadia)
iTBra FDA Class ll:
FDA class II Substantially changed devices will need to be reviewed before marketing clearance will be issued by the fda...
(simply put can’t market the device due to device applied application time/ AI software changes are re approved )
Your Probably aware the iT Bra went through technology upgrades, these changes substantially changed the
efficacy for the better, but still need FDA review.
This is why their website states-“The product is not currently available for sale in the United States.“
& Cyrcadia Asia states ”FDA Class II clearance issued with further clearances in process.”
Will Covid-19 hasten or impede the FDA & US continued trial...will see ! iFlytec(Keda Xunfei) & Cyrcadia Health
post# 27374
Re-Post: New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the iTBra tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some iTBras...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
#27171 PHd cancer researcher perspective Hint: U may be induced to buy more shares!
27131 PPS it’s long,but conclusion: pps.22 or more
27094 Co marketing intent: the short “it’s happening”!
27061 Market size & Need: Summary-It’s Huge & Needed
26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$
27037 Number of breast cancer cases & importance of earl detection: Your life may depend on it
26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Bloomberg Nov, 2017 iFlytec video (6 months After Cyrcadia Asia iT Bra investment)
“China’s iFlytec focuses on smart healthcare” quoted...
—“Smart Healthcare growth (acquisition) is the primary Company smart tech strategic focus”
—Assisted diognostic system accuracy for improved cancer diognosis through AI imaging”
—“Out International strategy of investing in USA Co’s WILL assist this goal”
—Activities are being conducted at our new Silicon Valley...
Read between the lines, LLBO S/B trading above .05 cents per share.
Jim Holmes, Lifeline’sCyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually”. (PPS anybody’s guess ?)
Damn she’s back, thought maybe the Covid-19 had buried U...13
Some...where overrrrr the Rainbow :)
$500 invest now (1Mil Shares) ~ $140,000 (.14Cents) down the gold brick road...!!! Clinical trial will come to an end & FDA will rule...?
I like the odds...13